TikoMed AB, of Uppsala, Sweden, received FDA orphan drug designation for TM-400 in the mobilization of stem cells prior to stem cell transplant...The product previously secured orphan drug designation in Europe

NurOwn is based on the use of adult human mesenchymal stem cells and has orphan drug designation in ALS...Remicade previously received orphan drug status for pediatric use, and the biologics license application has received priority review

4SC AG, Planegg-Martinsried, Germany, received orphan drug designation from the FDA for resminostat in hepatocellular cancer

The company previously was granted orphan drug status for NurOwn, a process involving the use of adult human mesenchymal stem cells derived from patients' bone marrow

4SC AG, Planegg-Martinsried, Germany, received orphan drug designation from the FDA for resminostat in hepatocellular cancer

Acorda expects to apply for FDA orphan drug designation for the acute treatment of SCI and will explore orphan drug designations in Europe and elsewhere

Immune System Therapeutics Ltd., of Sydney, Australia, received orphan drug designation from the FDA for MDX-1097, its antibody treatment for terminal blood cancer

The FDA granted orphan drug designation last year...Immune System Therapeutics Ltd., of Sydney, Australia, received orphan drug designation from the FDA for MDX-1097, its antibody treatment for terminal blood cancer

Accentia Biopharmaceuticals Inc., of Tampa, Fla., reported that the FDA granted orphan drug designation to Revimmune for the treatment of systemic sclerosis and autoimmune hemolytic anemia...The enzyme replacement therapy has already received orphan drug designation in the U.S

The company said the program has FDA orphan drug status as a conditioning treatment for use in autologous transplant for patients with multiple myeloma

Lamellar Biomedical Ltd., of Glasgow, Scotland, secured European orphan drug status for LMS-611 in the treatment of cystic fibrosis

Lamellar Biomedical Ltd., of Glasgow, Scotland, secured European orphan drug status for LMS-611 in the treatment of cystic fibrosis

Tengion Inc., of East Norriton, Pa., said the FDA granted orphan drug status to the firm's Neo-Urinary Conduit for treating bladder dysfunction requiring incontinent urinary diversion

Edison Pharmaceuticals Inc., of Mountain View, Calif., said the FDA granted orphan drug designation to EPI-743 for the treatment of inherited mitochondrial respiratory chain diseases, which affects about 60,000 people

In other news, Evotec acquired South San Francisco-based Compound Focus Inc., a division of BioFocus, part of Galapagos NV...SASPject is designed to deactivate bacteria and prevent any release of toxins and other inflammatory cell components from both target and nontarget bacteria, to minimize toxicity

The FDA granted orphan drug status to recombinant human erythropoietin by XTL Biopharmaceuticals Ltd., of Herzliya, Israel, for multiple myeloma

It already has orphan drug status in the U.S

NeuroHealing Pharmaceuticals Inc., of Newton, Mass., said the European Commission granted orphan drug designation for NH001 for treating patients following moderate or severe traumatic brain injury

The European Medicines Agency's Committee for Orphan Medicinal Products granted TikoMed AB, of Uppsala, Sweden, orphan drug designation for its TM-400 to mobilize progenitor cells prior to stem cell transplantation